A limitation of this study is that all CLN3 patientderived replicates originate from a single individual
With over 150 MILLION users of his transformation programs, nobody can dispute Kris' unrivaled authority of helping people transform their body no matter their circumstances
01 1Bioquim 02 1Basic Nutrition 03 1Willow Birch Pharma 04 1Gangwal Healthcare 05 1Sumar Biotech 06 1Anlon Healthcare Ltd 07 1Chongqing DaXin Pharmaceutical 08 1Gurvey & Berry 09 1Hanways Chempharm 10 1Jin Dun Medical 11 1Mac-Chem Products (India) Pvt.Ltd 12 2Shenzhen GSH Bio-tech Co., Ltd 13 1Summit Ingredients 14 1Xian Tian Guangyuan Biotech 15 1Zhejiang Hisun Chemical Co., Ltd
Disclosures: Sai Santosh Babu Komakula: Nothing to Disclose, Xiaodong Ge: Nothing to Disclose, Wei Chen: Nothing to Disclose, Romain Desert: Nothing to Disclose, Hui Han: Nothing to Disclose, Zhuolun Song: Nothing to Disclose, Sukanta Das: Nothing to Disclose, Dipti Athavale: Nothing to Disclose, Nithyananthan Subramaniyam: Nothing to Disclose, Chao Wang: Nothing to Disclose, Dan Lantvit: Nothing to Disclose, Abid Anwar: Nothing to Disclose, Natalia Nieto: Nothing to Disclose 2637 PRIMARY GRAFT DYSFUNCTION AND MAJOR ADVERSE CARDIAC EVENTS AFTER HEPATITIS C VIREMIC HEART TRANSPLANTATION TO AVIREMIC RECIPIENTS Ritika Mazumder 1 Sarah Khan 1 Sakthi Surya Prakash 1 Qijun Yang 1 Omar Sims 1 Randall Starling 1 William Carey 1 , 1 Cleveland Clinic Foundation Background: Although direct-acting antiviral therapy (DAA) has enabled successful use of hepatitis C (HCV) positive allografts with favorable short-term outcomes, there is a notable absence of studies comprehensively examining cardiac events following HCV viremic heart transplantation
Rev BrasTer Intensiva 2022;34:28794
